A long-term developer of companies with ambitious science and the ability to tackle major medical challenges

Portfolio

Flerie invests in venture and growth stage companies engaged in drug development and associated tools or applications tackling major medical challenges of our time

Geneos Therapeutics is a US-based clinical stage biotherapeutics company within the immunotherapy space. The GT-EPIC™ platform allows Geneos to develop exquisitely personalized DNA vaccines tailored to each patient's unique tumour mutations.

NorthX Biologics is a Swedish pharmaceutical company with a focus on process development and large-scale production of advanced biological drugs. The Swedish Government has given Vinnova (Sweden's innovation agency) the mandate to support the establishment of an innovation hub alongside NorthX Biologics in Matfors.

Xspray Pharma is a pharmaceutical company with several product candidates in clinical development. It uses its innovative, patented RightSize™ technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer.

Prokarium is a clinical stage venture developing microbial immunotherapies, leading with a therapeutic for Bladder Cancer and a vaccine for Enteric Fever, the latter in partnership with Wellcome.

Symcel is a medtech company developing an analytical instrument for direct metabolic measurements. In commercial phase on R&D markets with early traction and KOL support, in development of precision diagnostics for infectious diseases.

KAHR is a clinical stage cancer immunotherapy company developing novel bi-functional fusion proteins. KAHR's lead product, DSP107, is a first-in-class CD47x41BB targeting agent currently in clinical development for patients with solid tumors.

current investments

former investments

Cobra Biologics is a contract manufacturer of plasmid DNA, viral vector and microbiota products from pre-clinical through to clinical and commercial manufacture within GMP approved facilities. Cobra was divested to Cognate BioServices in 2020.

Cormorant repositioned a fully human mAb acquired from Genmab. HuMax-IL8 was brought to clinic as an immuno-oncology agent in solid tumor patients in collaboration with the NCI in the US and in 2016 Cormorant was sold to BMS for a total consideration of 520 MUSD.

Wilson Therapeutics was a Swedish biopharmaceutical company that developed a novel therapy for a rare disease. It was acquired by Alexion in 2018.

we invest

in people

We pride ourselves in being long-term people builders and we expect superior achievements in return

OUR TEAM ALL HAVE OPERATIONAL EXPERIENCE RUNNING BIOTECH AND PHARMA BUSINESSES THEMSELVES

Based in Stockholm and London and with investments across the EU, UK, US and Israel, the beginnings of Flerie Invest started with Thomas Eldered, co-founder and builder of Recipharm, which within 25 years became the fifth largest pharma CDMO in the world...

Thomas Eldered

Executive Chairman

Ted Fjällman

Chief Executive Officer

Cecilia Schéele

Chief Financial Officer

Mark Quick

Partner

Carl-Johan Spak

Senior Advisor

Gunilla Rydquist

Office Manager

Karl Elmqvist

Investment Manager

Carlos Von Bonhorst

Senior Advisor, Research & Business Innovation

Learning from peers in the same industry is a cornerstone in our philosophy and Flerie Invest has created fora to facilitate this

flerie

and peers

Portfolio peers exchange throughout the year and selected CEOs meet for a gathering in the wilderness

We have a deep network in the anglo-nordic pharma ecosystem and have a physical presence in Stockholm and London